Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Fatigue, perceived stigma, self-reported cognitive deficits and psychological morbidity in patients recovered from COVID-19 infection

Sandeep Grover, Swapnajeet Sahoo, Eeptsita Mishra, Kanwarbir Singh Gill, Aseem Mehra, Ritu Nehra, Aarzoo Suman, Ashish Bhalla, Goverdhan Dutt Puri

Abstract

Background: Few studies have highlighted multiple psychosocial and physical outcomes in patients with COVID-19 infection after recovery. However, the data from developing countries is limited.

Aim: To evaluate psychological morbidity, post-traumatic stress disorder (PTSD), fatigue, and perceived stigma among patients with COVID-19 after recovery from the acute phase of COVID-19 infection.

Methods: In a cross-sectional online survey, 206 adult patients (age > 18 years), recovered from COVID-19 infection completed the Patient Health Questionnaire-4 (PHQ-4), the Impact of Events Scale-Revised (IES-R), Fatigue Severity Scale (FSS), 4 items self-designed questionnaire evaluating cognitive deficits and self-designed questionnaire to evaluate perceived stigma. Additionally, they completed the information about demographic and clinical information.

Results: The prevalence of anxiety, depressive symptoms, and PTSD in the study sample was 24.8 %, 23.8 %, and 30 % respectively. About three-fifths of the participants (61.2 %) had at least one fatigue symptom as per the FSS with the mean FSS score being 32.10 ± 15.28. About one-fourth of the participants (23.7 %) reported “feeling confused and always feeling mentally foggy”, and 38 % of patients reported experiencing at least one cognitive problem. The level of felt stigma related to self was seen in 31.1 %, 20 % reported stigma related to family, and 50 % reported stigma in relation to neighbors and society. Those reporting higher PTSD scores had higher anxiety and depressive scores, reported more fatigue and stigma, and had a higher level of cognitive deficits. A higher fatigue score was also associated with higher anxiety, depression, and cognitive deficits.

Conclusions: Our study reveals that a significant proportion of patients after recovery from COVID-19 experience psychological morbidities, fatigue, cognitive problems, and stigma. Efforts should be made to take care of these issues in routine post-COVID follow-up care.

Introduction

COVID-19 pandemic has emerged as a severe crisis, involving multiple domains such as unemployment, financial crisis, severe health sector crisis, deaths of family members, and multiple long-standing post-COVID physical consequences. Many studies have shown that the survivors of COVID-19 infection have a higher prevalence of psychological morbidities (Rogers et al., 2020; Taquet et al., 2021), neurological complications (Taquet et al., 2021), fatigue (Garg et al., 2021; Stavem et al., 2021; Townsend et al., 2020), cognitive deficits or ‘mental slowing’/’Brain Fog’ (Landau, 2021; Zhou et al., 2020) and stigma (Bagcchi, 2020; Villa et al., 2020). Data from a large scale study (n = 236,379) of patients diagnosed with COVID-19 infection revealed the estimated incidence of a neurological or psychiatric diagnosis in the 6 months follow up period to be 33.62 % and those admitted to an intensive care unit (ICU) had an incidence rate of 46.42 % (Taquet et al., 2021). Psychiatric diagnosis specific outcome as reported by the study suggested incidences of 0.67 % for dementia, 17.39 % for anxiety disorder, and 1.4 % for psychotic disorder with higher rates in those admitted in ICU during the acute illness (Taquet et al., 2021). Data also suggests the prevalence of post-traumatic stress symptoms (PTSS) or post-traumatic stress disorder.
factors contributing to these outcomes can be quite different in developing countries. The psychosocial perspectives (Baldassarre et al., 2020; Villa et al., 2020).

The emerging data also provides evidence for the direct effect of the SARS-CoV-2 on the human central nervous system leading to neuropsychiatric sequelae such as mood changes, psychosis, and neuromuscular dysfunction during the recovery period (Trorey et al., 2020).

Among the physical outcomes of COVID-19, fatigue has received significant attention. Available data suggest a high prevalence of fatigue (ranging from 46 to 53 %) in the COVID-19 survivors (Qi et al., 2020; Stavem et al., 2021). The fatigue has been reported to be independent of the severity of the initial infection (Townsend et al., 2020). In terms of factors associated with fatigue emerging data indicate a higher prevalence of fatigue among females, those having pre-existing depression/anxiety, Vitamin D deficiency, hypothyroidism, iron deficiency anemia, and Vitamin B12 deficiency (Garg et al., 2021; Townsend et al., 2020). Further, there has been emerging data suggesting evidence for cognitive deficits and dementia in the patients recovered from COVID-19 infection (Beaud et al., 2020; Zhou et al., 2020).

Among the social outcomes, stigma has received some attention and it is considered to a significant contributor to poor mental health during the recovery period. Patients with COVID-19 have been the victims of severe social stigmatization during the acute phase of illness, during the quarantine period, and also during the recovery period (Bagcchi, 2020). Being labeled as “super-spreader”, “infecting the community” etc. further adds to the agony of the COVID-19 survivors (Bhattacharya et al., 2020). Patients with COVID-19 during their hospital stay report significant self-stigma, anticipatory stigma from family, and neighbors/society (Sahoo et al., 2020). However, stigma although is expected to affect the individual during the recovery period is not yet been explored in detail, and data in this regard is the form of viewpoints and perspectives (Baldassarre et al., 2020; Villa et al., 2020).

The data on the psychological morbidity, fatigue and reported stigma among patients with COVID-19 after recovery from the acute infection from the developing countries is limited. The psychosocial factors contributing to these outcomes can be quite different in developing countries compared to the Western countries. Therefore, the current study was planned with an aim to evaluate psychological morbidity, PTSD, fatigue, cognitive deficits and perceived stigma among patients with COVID-19 after recovery from the acute phase of COVID-19 infection.

2. Methodology

It was a cross-sectional online survey that included 206 adult patients (age > 18 years) who had recovered from COVID-19 infection. As a part of post-COVID follow-up, the patients admitted to our setup, are assessed for any psychological morbidity after 4–6 weeks of discharge. The study sample comprised of recovered patients (admitted to our setup), and we also followed a snowball sampling technique by asking the patients to circulate the survey link to their known contacts who had recovered from COVID-19 infection.

The study questionnaire included self-designed questions to collect information about the demographic factors, COVID-19 infection (days since recovery, number of days admitted inwards/ICUs, etc.), psychological morbidity, PTSD, stigma, cognitive deficits, and fatigue. The depressive and anxiety symptoms were assessed by using the Patient Health Questionnaire-4 (PHQ-4) (Kroenke et al., 2009), which is a self-administered, ultra-brief screening instrument to detect both depression and anxiety. It has 2 items each from PHQ-9 and Generalized Anxiety Questionnaire-7. The PTSD was assessed by using the Impact of Events Scale-Revised (IES-R), which is a self-reported 22 items scale. This is a validated scale that has been used in many studies (Weiss and Marmar, 2004). Fatigue was evaluated by using the Fatigue Severity Scale, which is a 9-item self-reported questionnaire developed to assess fatigue in patients with systemic lupus erythematosus, multiple sclerosis, etc (Krupp et al., 1989). Perceived stigma was assessed by using a self-designed questionnaire to assess the overall experience of self-stigma, stigma related to family, and society/neighbors. Each item was rated on a 5 point scale (0–4, with a higher score indicating higher stigma). The cognitive symptoms were assessed by using a 4 item self-designed questionnaire evaluating problems faced by the patients in the domains of attention/concentration and in performing the daily tasks. Each item was rated on a 4 point scale (0–3, with a higher score indicating higher dysfunction).

An online survey link was generated using the Google form consisting of all the above-mentioned questionnaires and was circulated through Whatsapp. The study was approved by the Institute’s Ethics committee. The survey cover letter explicitly mentioned that completion of the survey implied informed consent and non-participation in the survey would have no consequences and the recipients can ignore the survey link. Additionally, the cover letter also mentioned responding only if the subject had suffered from COVID-19 infection and ignoring if they had not. We took care of duplicate entries by screening the IP addresses of the responses.

The data so collected were analyzed using SPSS software, version 20.0. Descriptive statistics were applied. Pearson’s /Spearman’s correlation coefficient was used to evaluate the association between different variables.

3. Results

During the study period 6th May to 2nd June 2021, 206 persons recovered from COVID-19 infection completed the survey and formed the study sample.

The mean age of the participants was 36.08 (SD-13.12) years (range – 18–72 years), with 8% of participants aged more than 60 years. More than half of the participants were males (53.9 %) and married (56.3 %). The majority of the participants were educated with graduate or post-graduate qualifications and one-third of respondents were doctors (36.9 %). About two-thirds of the participants were admitted to COVID wards during the acute phase infection with only 8% being admitted to ICUs. The majority of the participants were admitted alone (57.3 %) and were infected alone in their families (58.7 %). The mean duration of hospital stay was around 11.3 (SD-6.52) days and the mean duration of ICU stay for those required ICU care was 10.7 (SD-4.39) days. Further, about one-fifth (22.8 %) reported having seen someone dying during their hospital stay in ICU/wards. The mean duration of days since discharge from the hospital or having recovered from the acute stage was 33.72 (SD-49.52) days at the time of completing the survey. About one-fourth of the participants had comorbid medical conditions (27.7 %) (Table 1).

On PHQ-4, the mean anxiety score was 1.55 (SD-1.63) and the mean depressive score was 1.43 (1.68). The prevalence of anxiety and depression was found to be 10.2 % and 9.2 % respectively, with an overall prevalence of both anxiety and depression being 14.6 %. The mean IES-R score was 18.51 (SD-16.04) with 30 % of the participants reporting PTSS like symptoms. Partial PTSD and probable PTSD were found in 12 % and 2.9 % participants respectively, and 15 % of the participants reported definite PTSD as per the cut-off score of IES-R (Table 2).

4. Prevalence of Fatigue in recovered patients

Fatigue was evaluated on the FSS and as revealed from the specific items scores (Table 3), about 43 % agreed of having low motivation when fatigued (FSS-item 1), and reported exercise brings on fatigue (FSS-item 2). About two-fifths agreed that they are easily fatigued (FSS-
item 3), 44 % reported fatigue to be interfering with their physical functioning (FSS-item 4) and 36 % reported fatigue preventing them from sustained physical functioning (FSS-item 6). About 35 % reported fatigue interfering with carrying out duties and responsibilities (FSS-item 7). About one-third agreed that fatigue was among the three most disabling symptoms (FSS-item 8) and 35 % agreed to it interfering with work, family, and social life (FSS-item 9). The mean FSS score was 32.1 (SD-15.28) and the mean global fatigue level was 5.93 (SD-2.90) (Table 3).

5. Prevalence of self-reported cognitive deficits in recovered patients

The participants were asked to rate their cognitive functions on a 4 item Likert scale (ranging from 0 to 3), specifically designed to tap cognitive deficits (Table 4). About one-fourth of the participants (23.7 %) reported “feeling confused and always feeling mentally foggy”, and 31.5 % reported having a “lack of attention and concentration”, 22.3 % reported “forgetting recent things” and 18.4 % reported “forgetting past events”. The mean cognitive score was 1.43 (SD-2.45) (Table 4).

When enquired about felt stigma, overall, the level of felt stigma related to self was seen in 31.1 % (i.e., reported stigma on at least one of the items related to self), 20 % reported stigma related to family (i.e., reported stigma in at least one of the items related to family) and 50 %
reported stigma in relation to neighbors and society (i.e., reported stigma on at least one of the items related to neighbors/society) (Table 5).

Age, gender, marital status, presence/absence of physical illness, total duration of hospital stay, duration of ICU stay, and days since discharge/recovery were not found to have any significant association with anxiety, depression, PTSD, fatigue, felt stigma, and cognitive deficits. Those reporting higher PTSD scores had higher anxiety and depressive scores, reported more fatigue, reported higher level of and stigma and had a higher level of cognitive deficits (Table 6). A higher fatigue score was also associated with higher anxiety, depression, and cognitive deficits. Stigma was more strongly associated with PTSD, anxiety, and depression (Table 6).

6. Discussion

The data on the psychosocial and physical outcomes in patients with COVID-19 following recovery from COVID-19, infection is emerging.

Table 3
Prevalence of fatigue as reported in the Fatigue severity scale (FSS) in recovered patients (n = 206).

| Variables | Strongly disagree Frequency (%) | Slightly disagree Frequency (%) | Disagree Frequency (%) | Neutral Frequency (%) | Agree Frequency (%) | Agree to some extent Frequency (%) | Strongly agree Frequency (%) |
|-----------|---------------------------------|---------------------------------|------------------------|----------------------|---------------------|-----------------------------------|-----------------------------|
| 1. My motivation is lower when I am fatigued | 41 (19.9) | 24 (11.7) | 23 (11.2) | 28 (13.6) | 55 (26.7) | 19 (9.2) | 16 (7.8) |
| 2. Exercise brings on my fatigue | 43 (20.9) | 30 (14.6) | 21 (10.2) | 24 (11.7) | 51 (24.8) | 16 (7.8) | 21 (10.2) |
| 3. I am easily fatigued | 48 (23.8) | 27 (13.1) | 25 (12.1) | 22 (10.7) | 54 (26.2) | 15 (7.3) | 15 (7.3) |
| 4. Fatigue interferes with my physical functioning | 43 (20.9) | 30 (14.6) | 19 (9.2) | 23 (11.2) | 58 (28.2) | 16 (7.8) | 17 (8.3) |
| 5. Fatigue causes frequent problems for me | 47 (22.8) | 27 (13.1) | 29 (14.1) | 31 (15.0) | 43 (20.9) | 15 (7.3) | 14 (6.8) |
| 6. My fatigue prevents sustained physical functioning | 43 (20.9) | 32 (15.5) | 23 (11.2) | 33 (16.0) | 44 (21.4) | 20 (9.7) | 11 (5.3) |
| 7. Fatigue interferes with carrying out certain duties and responsibilities. | 51 (24.8) | 25 (12.1) | 26 (12.6) | 32 (15.5) | 44 (21.4) | 13 (6.3) | 15 (7.3) |
| 8. Fatigue is among my three most disabling symptoms | 47 (22.8) | 28 (13.6) | 31 (15.0) | 31 (15.0) | 30 (14.6) | 19 (9.2) | 20 (9.7) |
| 9. Fatigue interferes with my work, family, or social life | 45 (21.8) | 26 (12.6) | 33 (16.0) | 29 (14.1) | 43 (20.9) | 16 (7.8) | 14 (6.8) |
| Mean FSS score (SD) | 32.10 (15.28) | Range : 9 – 63 | Median – 35.0 |
| Rate your level of fatigue /global fatigue on the scale from 0 to 10 ; “0” being worst and “10” being normal. | 5.93 (2.90) | Median – 6.0 |
| Number of patients reporting at least one fatigue symptom (agree/agree to some extent/strongly agree) | 126 (61.2) |
Fatigue has been reported to be one of the significant presenting complaints during the acute phase of COVID-19 infection (44–70%) (Huang et al., 2020; Wang et al., 2020) and also had now been recognized to be quite prevalent (46–53%) in the post-recovery period (Staevem et al., 2021; Townsend et al., 2020). The present study also found about three-fifths of the participants (61.2%) having at least one fatigue symptom as per the FSS. More particularly, about two-fifths (40%) reported feeling easily fatigued (FSS-item 3), and about one-third agreed that fatigue was among the three most disabling symptoms (FSS-item 8). These findings suggest that there is a high prevalence of fatigue after variables like the duration of hospital stay, having seen anyone dying in ICU, admission to ICU, being admitted alone, etc. Similar findings have been reported by an Italian study suggesting no significant correlation/association between duration of hospitalization, the severity of disease, or ICU care with psychological outcomes and PTSD (Bonazza et al., 2021). These findings are in sharp contrast with the literature available during the pre-COVID era, where admission to an ICU set up, type of treatment being provided (such as administration of sedatives) and different ICU clinical factors (such as ICU delirium) to be contributing to the development of post-ICU PTSD (Davydow et al., 2006; Kwek et al., 2006).

Long term psychological and neurological sequelae are being reported from different parts of the globe (Hao et al., 2020; Nalleballe et al., 2020; Rogers et al., 2020; Taquet et al., 2021; Varatharaj et al., 2020). Additionally, studies suggest a bidirectional relationship between COVID-19 and the development of psychiatric disorders (Taquet et al., 2020; Wang et al., 2021). However, the research on specific psychosocial outcomes is limited. In this regard, the current study findings add to the data on psychosocial and physical outcomes.

As evident from the study findings, the prevalence of anxiety, depression and PTSD in the study sample was 24.8%, 23.8%, and 30%, respectively. Overall prevalence of concomitant anxiety and depression was found to be 14.6% and definite PTSD (as per IES-R) to be 15%. The overall prevalence of concomitant anxiety and depression and PTSD in the study sample was 24.8%, 23.8%, and 30%, respectively. Overall prevalence of concomitant anxiety and depression was found to be 14.6% and definite PTSD (as per IES-R) to be 15%.

| Variables                                               | Never (0) | Sometimes (1) | Often (2) | Usually (3) |
|---------------------------------------------------------|-----------|---------------|-----------|-------------|
| Are you worried that others will come to know that you suffered from COVID-19 | 156 (75.7) | 35 (17.0)     | 11 (5.3)  | 4 (1.9)     |
| Are you trying to hide, about your COVID-19 infection from others | 175 (85.0) | 21 (10.2)     | 6 (2.9)   | 4 (1.9)     |
| You are feeling ashamed because you tested positive for COVID-19 infections | 183 (88.8) | 16 (7.8)      | 6 (2.9)   | 1 (0.5)     |
| You are feeling embarrassed because you tested positive for COVID-19 infections | 183 (88.8) | 19 (9.2)      | 2 (1.0)   | 2 (1.0)     |
| People in your family are avoiding you | 184 (72.3) | 15 (7.3)      | 6 (2.9)   | 1 (0.5)     |
| People in your family are unkind to you | 183 (88.8) | 18 (8.7)      | 3 (1.5)   | 2 (1.0)     |
| People in your family are uncomfortable with you | 191 (92.7) | 10 (4.9)      | 4 (1.9)   | 1 (0.5)     |
| People in your family are afraid of you, because of your COVID-19 positive status in the past | 185 (89.8) | 15 (7.3)      | 4 (1.9)   | 2 (1.0)     |
| People in your family avoid touching you, because of your COVID-19 positive status in the past | 180 (87.4) | 16 (7.8)      | 7 (3.4)   | 3 (1.5)     |
| Number of patients reporting stigma (sometime/often/usually) in at least one of the items | 64 (31.1)  |               |           |             |
recovery from COVID-19 infection which is linked with greater psychological morbidity. Previous studies have reported female gender, being single, high symptom load and confusion during the acute COVID-19 infection, and pre-existing diagnosis of depression/anxiety, presence of co-morbid hypothyroidism and anemia to be strongly associated with fatigue post-COVID (Garg et al., 2021; Stavem et al., 2021; Townsend et al., 2020) and no association of fatigue with severity of COVID-19 infection (ICU admission, oxygen requirement), and routine laboratory inflammatory marker levels (Townsend et al., 2020). In contrast to these findings, our study did not find any significant association of fatigue with any of the acute COVID-19 infection-related variables (duration of hospital stay, duration of ICU stay, days since recovery, age, gender, marital status, presence of medical co-morbidities) and fatigue post-COVID (although we did not have data about inflammatory markers). Depression is a mediator of chronic fatigue and PTSS symptoms in MERS survivors (Lee et al., 2019). The present study also revealed a strong association between anxiety and depressive symptoms and fatigue post-COVID-19, suggesting mediating effects of depression/anxiety in experiencing post-COVID fatigue. There has been an increasing concern that COVID-19 can trigger various post-viral fatigue syndromes shortly (Wilson, 2020; Wong and Weitzen, 2021). Therefore, mental health morbidities’ evaluation is of utmost importance to address and treat fatigue post COVID.

Another important outcome in the post-COVID period reported in some of the studies includes cognitive deficits or mental confusion (Zhou et al., 2020). The spectrum of cognitive deficits can range from mild cognitive dysfunction/impairment to severe dementia (Di Pietro et al., 2021; Vanderlind et al., 2021). Self-reporting of cognitive deficits is considered as one of the early intervention strategies to detect mild cognitive impairment and dementia in the community (Kasai et al., 2021). Therefore, using a self-reported cognitive symptom questionnaire can be regarded as a useful strategy to screen cognitive deficits in individuals who have recovered from COVID-19. In the present study, about two-fifths (38.3 %) of the participants had at least one self-reported cognitive symptom. However, as previous studies have not reported on the prevalence of cognitive deficits, it isn’t easy to compare the findings with the existing literature. Therefore, the study’s findings should be considered preliminary, which calls for a detailed evaluation of cognitive function in future studies. However, the exact course of cognitive sequelae is limited by the lack of longitudinal studies on the cognitive profile of recovered patients. Hence in the future, more studies with the use of clinical and neuropsychological tests with longitudinal study design will be beneficial to tap the exact prevalence and course of cognitive deficits in recovered patients in the community.

Stigma can be regarded as one of the greatest social consequences of COVID-19 infection. There have been reports of significant discrimination of healthcare workers on COVID-19 duties (Bagcchi, 2020; Battacharya et al., 2020), stigma against colleagues (Grover et al., 2020), and anticipatory stigma from the society in the hospitalized patients with COVID-19 infection (Sahoo et al., 2020). The present study suggests that a significant proportion of patients have self-stigma (31 %), stigma related to family members (20.9 %), and high felt stigma related to other members of the society (at least one item -50 %). These findings highlight the widespread prevalence of stigma in public for COVID-19, which requires urgent attention and awareness at a global level.

We are well aware of our limitations. Some of these include a web-based cross-sectional survey on a limited number of patients, the use of screening questionnaires to assess psychological morbidity, and relying on self-reported responses by the participants. Future studies with a longitudinal study design on a larger sample would help estimate the prevalence, course, and outcome of psychological morbidities, fatigue, cognitive deficits, and stigma in a better way.

To conclude, the present study reveals that a significant proportion of patients after recovery from COVID-19 experience psychological morbidities (anxiety -24.8 %, depression-23.8 % and PTSD-30 %), 60 % experience at least one fatigue symptom, and 38 % experience cognitive

### Table 6

| Variables                      | Total IES-R | PHQ-4 anxiety score | PHQ-4 depression score | Total PHQ-4 score | Total FSS score | Cognitive score | Total stigma score |
|--------------------------------|-------------|---------------------|------------------------|-------------------|-----------------|-----------------|-------------------|
| Age                            | 0.117 (.095) | 0.055 (.429)        | 0.055 (.429)           | 0.035 (.622)      | 0.118 (.092)    |                 | XX                |
| No of days in ICU              | 0.008 (.919) | 0.019 (.819)        | 0.043 (.596)           | 0.045 (.579)      | 0.015 (.836)    | XX              |                  |
| Days since discharge or recovery from illness | 0.0001 (.999) | 0.037 (.593) | 0.04 (.622)            | 0.032 (.649)      | XX              | XX              | XX                |
| PHQ-4 anxiety score            | 0.359 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |
| PHQ-4 depression score         | 0.476 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |
| Total PHQ-4 score              | 0.461 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |
| Total FSS score                | 0.321 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |
| Total Cognitive score          | 0.254 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |
| Total stigma score             | 0.242 (<0.001)*** | 0.415 (<0.001)*** | 0.482 (<0.001)***      | 0.662 (<0.001)*** | XX              | XX              | XX                |

* - Spearman’s correlation co-efficient.
deficit in at least one of the domains. Further, the study found the existence of a significant amount of felt/perceived stigma, mostly in relation to society/neighborhood in patients recovered from COVID-19 infection.

Financial disclosure
We have no financial disclosure to make.

Funding
No funding of any kind was received for this study.

Declaration of Competing Interest
All authors have no conflicts of interest to declare.

Acknowledgements
None.

References
Bagochi, S., 2020. Stigma during the COVID-19 pandemic. Lancet Infect. Dis. 20, 782. https://doi.org/10.1016/S1473-3099(20)30048-9.
Baldassarre, A., Giorgi, G., Alessio, F., Lulli, L.G., Arcangeli, G.,ucci, M., 2020. Stigma and discrimination (SAD) at the time of the SARS-CoV-2 pandemic. Int. J. Environ. Res. Public Health 17. https://doi.org/10.3390/ijerph170417641.
Beaud, V., Crottes-Herbet, S., Dunet, V., Vaucher, J., Bernard-Valnet, R., Pasquier, R. D., Bart, P.-A., Clarke, S., 2020. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-325175.
Bhattcharaya, P., Banerjee, D., Rao, T.S., 2020. The “wound” side of COVID-19: social stigma and its consequences in India. Indian J. Psychol. Med. 42, 382–386. https://doi.org/10.1076/ijpm.2019.30955786.
Bonazza, F., Borghi, L., di San Marco, E.C., Piscopo, K., Bai, F., Monforte, A’ d’ Arminio, Vegni, E., 2021. Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients. Res Psychother. 23. https://doi.org/10.4081/rripo.2020.491.
Castelli, L., Di Tella, M., Benfante, A., Romeo, A., 2020. The spread of COVID-19 in the italian population: anxiety, depression, and post-traumatic stress symptoms. Can. J. Psychiatry 65, 731–732. https://doi.org/10.1177/0706743720938598.
Chen, Y., Huang, X., Zhang, C., An, Y., Liang, Y., Yang, Y., Liu, Z., 2021. Prevalence and predictors of posttraumatic stress disorder, depression and anxiety among hospitalized patients with coronavirus disease 2019 in China. BMC Psychiatry 21, 80. https://doi.org/10.1186/s12888-021-00076-7.
Chew, N.W.S., Lee, G.K.H., Tan, B.Y.Q., Jing, M., Goh, Y., Ngiam, N.J.H., Yeo, L.L.L., Grover, S., Singh, P., Sahoo, S., Mehra, A., 2020. Quality of life and psychological status in survivors of severe acute respiratory syndrome at 3 months postdischarge. J. Psychosom. Res. 60, 513–519. https://doi.org/10.1016/j.jpsychores.2005.08.020.
Landewé, R., 2021. Brain Fog: COVID-19 Symptom That Can Linger | Everyday Health (WWN Document). EverydayHealth.com. URL: https://www.everydayhealth.com/coronavirus/brain-fog-a-covid-symptom-that-may-linger/ (accessed 6.18.21).
Lee, S.H., Shin, H.-S., Park, H.Y., Kim, J.I., Lee, J.J., Lee, H., Won, S.-D., Han, W., 2019. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle east respiratory syndrome survivors. Psychiatry Investig. 16, 59–64. https://doi.org/10.30773/pi.2018.10.22.3.
Liu, C.H., Zhang, E., Wong, G.T.F., Hynn, S., Hahm, H.C., 2020. Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: clinical implications for U.S. Young adult mental health. Psychiatry Res. 290, 113172. https://doi.org/10.1016/j.psychres.2020.113172.
Nalleballe, K., Reddy Oneddua, S., Sharma, R., Dandu, V., Brown, A., Jasti, M., Yadala, S., Veerapaneni, K., Siddamreddy, M., Saha, A., Kapoor, N., Mudanjan, K., Kevoru, S., 2020. Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav. 88, 71–74. https://doi.org/10.1002/brb3.2060.020.06.
Qi, R., Chen, W., Liu, S., Thompson, P.M., Zhang, L.J., Xia, F., Cheng, F., Hong, A., Song, W., Lan, S., Sun, J.Z., Zhou, C.S., Li, H., Jiang, Z., Hui, G.M., 2020. Psychological morbidities and fatigue in patients with confirmed COVID-19 during disease outbreak: prevalence and associated psychosocial risk factors. medRxiv. https://doi.org/10.1101/2020.05.20.20103666.
Rogers, L.P., Chenney, E., Oliver, L., Talia, T.A., McGuire, P., Farall, P., Zandi, M.S., Lewis, G., David, A.S., 2020. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 0. https://doi.org/10.1016/j.lanpsy.2020.10.025.
Stavek, K., Ghanima, W., Olsen, M.K., Gilhoe, H.M., Einvik, G., 2021. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int. J. Environ. Res. Public Health 18. https://doi.org/10.3390/ijerph18040491.
Taqut, M., Luciano, S., Geddes, J.R., Harrison, P.J., 2020. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62,515 COVID-19 cases in the USA. Lancet Psychiatry 0. https://doi.org/10.1016/S2215-0366(20)30203-0.
Taqut, M., Geddes, J.R., Husain, M., Luciano, S., Harrison, P.J., 2021. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health data. Lancet Psychiatry 8, 416–427. https://doi.org/10.1016/S2215-0366(20)30204-2.
Townsend, L., Dyer, A.H., Jones, K., Dunne, J., Mooney, A., Gaffney, F., O’Conner, L., Leavy, D., O’Brien, K., Dowds, J., Sugrue, J.A., Hopkins, D., Martin-Loeches, I., Chelliah, C.N., Nandakumar, R.P., Malaulah, A.B., Leong, C.J., O’Farrellly, C., Bannan, C., Conlon, N, 2020. Persistent fatigue following SARS-CoV-2 infection and independent of severity of initial infection. PLoS One 15, e0240784.https://doi.org/10.1371/journal.pone.0240784.
Troyer, E.A., Kohn, J.N., Hoog, S., 2020. Are we facing a crushing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 87, 34–39. https://doi.org/10.1016/j.bbi.2020.04.027.
Vanderlinde, M.W., Rabinowitz, B.B., Miao, L.Y., Oberlin, L.E., Bueno-Castellano, C., Fridman, C., Jaywant, A., Kanellopoulos, D., 2021. A systematic review of neuropsychological and psychiatric sequelae of COVID-19: implications for treatment. Curr. Opin. Psychiatry 34, 420–433. https://doi.org/10.1097/YCO.0000000000001071.
Varatharaj, A., Thomas, N., Elul, M.A., Davies, N.W.S., Pollak, T.A., Tenorio, E.L., Sultan, M., Easton, A., Breen, G., Zandi, M., Coles, J.P., Manji, H., Al-Shahi Salman, R., Menon, D.K., Nicholson, T.R., Benjamin, L.A., Carson, A., Smith, C., Turner, K.R., Solomon, T., Koron, B., Petrie, A.M., Ho, C.S.H., Reddy, B.D., CoroNerve Study Group, 2020. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7, 482–483. https://doi.org/10.1016/S2215-0366(20)30528-4.
Villa, S., Jaramillo, E., Mangioni, D., Bandera, A., Goti, A., Raviglione, M.C., 2020. Stigma at the time of the COVID-19 pandemic. Clin. Microbiol. Infect. 26, 1450–1452. https://doi.org/10.1016/j.cmi.2020.08.011.
Vindevogel, N., Bensro, M.E., 2020. Neuropsychiatric and mental health consequences: systematic review of the current evidence. Brain Behav. Immun. 89, 531–542. https://doi.org/10.1016/j.bbi.2020.05.048.
Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., Ho, C.S., Ho, R.C., 2020. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int. J. Environ. Res. Public Health 17. https://doi.org/10.3390/ijerph17051728.
Wang, P.R., Oyem, P.C., Viguera, A.C., 2021. Prevalence of psychiatric morbidity following discharge after COVID-19 hospitalization. Gen. Hosp. Psychiatry 69, 131–132. https://doi.org/10.1016/j.genhosppsych.2020.12.013.

Weiss, D., Marmar, C., 2004. The impact of event scale - revised. In: Wilson, J.P., Keane, T.M. (Eds.), Assessing Psychological Trauma and PTSD. Guilford Press, New York, USA, pp. 399–411.

Wilson, C., 2020. Concern coronavirus may trigger post-viral fatigue syndromes. New Sci. 246, 10–11. https://doi.org/10.1016/S0262-4079(20)30746-6.

Zhou, H., Lu, S., Chen, J., Wei, N., Wang, D., Lyu, H., Shi, C., Hu, S., 2020. The landscape of cognitive function in recovered COVID-19 patients. J. Psychiatr. Res. 129, 98–102. https://doi.org/10.1016/j.jpsychires.2020.06.022.